Investors

investor-photo2

Enanta Pharmaceuticals is a clinical stage biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and immunological diseases. Enanta’s research and development efforts include programs in the following disease areas: respiratory syncytial virus (RSV), SARS-CoV-2 (C0VID-19) and hepatitis B Virus (HBV) and chronic spontaneous urticaria (CSU).

Learn More »

Volume:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent Press Releases

April 30, 2024
Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 30, 2024
Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

Upcoming Events